Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Expression of HERC4 in Lung Cancer and its Correlation with Clinicopathological Parameters

  • Zeng, Wen-Li (Institute of Genetic Engineering, Southern Medical University) ;
  • Chen, Yao-Wu (Institute of Genetic Engineering, Southern Medical University) ;
  • Zhou, Hui (Institute of Genetic Engineering, Southern Medical University) ;
  • Zhou, Jue-Yu (Institute of Genetic Engineering, Southern Medical University) ;
  • Wei, Min (Institute of Genetic Engineering, Southern Medical University) ;
  • Shi, Rong (Institute of Genetic Engineering, Southern Medical University)
  • Published : 2015.02.25
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Growing evidence suggests that the members of the ubiquitin-proteasome system (UPS) are important for tumorigenesis. HERC4, one component, is a recently identified ubiqutin ligase. However, the expression level and function role of HERC4 in lung cancer remain unknown. Our objective was to investigate any correlation between HERC4 and development of lung cancer and its clinical significance. Materials and Methods: To determine HERC4 expression in lung cancer, an immunohistochemistry analysis of a tissue microarray containing samples of 10 lung normal tissues, 15 pulmonary neuroendocrine carcinomas, 45 squamous epithelial cancers and 50 adenocarcinomas was conducted. Receiver operating characteristic (ROC) curve analysis was applied to obtain a cut-off point of 52.5%, above which the expression of HERC4 was regarded as "positive". Results: On the basis of ROC curve analysis, positive expression of HERC4 was detected in 0/10 (0.0%) of lung normal tissues, in 4/15 (26.7%) of pulmonary neuroendocrine carcinomas, in 13/45 (28.9%) of squamous epithelial cancers and in 19/50 (38.0%) of adenocarcinomas. It showed that lung tumors expressed more HERC4 protein than adjacent normal tissues (${\chi}^2$=4.675, p=0.031). Furthermore, HERC4 positive expression had positive correlation with pT status (${\chi}^2$=44.894, p=0.000), pN status (${\chi}^2$=43.628, p=0.000), histological grade (${\chi}^2$=7.083, p=0.029) and clinical stage (${\chi}^2$=72.484, p=0.000), but not age (${\chi}^2$=0.910, p=0.340). Conclusions: Our analysis suggested that HERC4 is likely to be a diagnostic biomarker for lung cancer.

Keywords

References

  1. Begum S, Brait M, Dasgupta S, et al (2011). An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res, 17, 4494-503. https://doi.org/10.1158/1078-0432.CCR-10-3436
  2. Brothers JF, Hijazi K, Mascaux C, et al (2013). Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-national lung screening trial era. BMC Med, 11, 168. https://doi.org/10.1186/1741-7015-11-168
  3. Deng CX, Scott F (2000). Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene, 19, 1059-64. https://doi.org/10.1038/sj.onc.1203269
  4. Deshaies RJ, Joazeiro CA (2009). RING domain E3 ubiquitin ligases. Annu Rev Biochem, 78, 399-434. https://doi.org/10.1146/annurev.biochem.78.101807.093809
  5. Hickey CM, Wilson NR, Hochstrasser M (2012). Function and regulation of SUMO proteases. Nat Rev Mol Cell Biol, 13, 755-66. https://doi.org/10.1038/nrm3478
  6. Hochrainer K, Mayer H, Baranyi U, et al (2005). The human HERC family of ubiquitin ligases: novel members, genomic organization, expression profiling, and evolutionary aspects. Genomics, 85, 153-64. https://doi.org/10.1016/j.ygeno.2004.10.006
  7. Jemal A, Center MM, DeSantis C, et al (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19, 1893-907. https://doi.org/10.1158/1055-9965.EPI-10-0437
  8. Ji Y, Walkowicz MJ, Buiting K, et al (1999). The ancestral gene for transcribed, low-copy repeats in the prader-willi/angelman region encodes a large protein implicated in protein trafficking, which is deficient in mice with neuromuscular and spermiogenic abnormalities. Hum Mol Genet, 8, 533-42. https://doi.org/10.1093/hmg/8.3.533
  9. Kuhn DJ, Chen Q, Voorhees PM, et al (2007). Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitinproteasome pathway, against preclinical models of multiple myeloma. Blood, 110, 3281-90. https://doi.org/10.1182/blood-2007-01-065888
  10. Lindsten K, Dantuma NP (2003). Monitoring the ubiquitin/proteasome system in conformational diseases. Ageing Res Rev, 2, 433-49. https://doi.org/10.1016/S1568-1637(03)00031-X
  11. Melvin AT, Woss GS, Park JH, et al (2013). Measuring activity in the ubiquitin-proteasome system: from large scale discoveries to single cells analysis. Cell Biochem Biophys, 67, 75-89. https://doi.org/10.1007/s12013-013-9621-9
  12. Rodriguez CI, Stewart CL (2007). Disruption of the ubiquitin ligase HERC4 causes defects in spermatozoon maturation and impaired fertility. Dev Biol, 312, 501-8. https://doi.org/10.1016/j.ydbio.2007.09.053
  13. Tomohiro M, Mizuno A (1995). Alteration of lens sulfhydryl groups induced by oxidative stress: Raman spectroscopic study of hydrogen peroxide-treated rat lens. Jpn J Ophthalmol, 39, 130-6.
  14. Vendetti FP, Rudin CM (2013). Epigenetic therapy in non-smallcell lung cancer: targeting DNA methyltransferases and histone deacetylases. Expert Opin Biol Ther, 13, 1273-85. https://doi.org/10.1517/14712598.2013.819337

Cited by

  1. The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice vol.127, pp.13, 2016, https://doi.org/10.1182/blood-2015-07-658203
  2. Functional and pathological relevance of HERC family proteins: a decade later vol.73, pp.10, 2016, https://doi.org/10.1007/s00018-016-2139-8
  3. "Stealth dissemination" of macrophage-tumor cell fusions cultured from blood of patients with pancreatic ductal adenocarcinoma vol.12, pp.9, 2017, https://doi.org/10.1371/journal.pone.0184451
  4. HERC4 Is Overexpressed in Hepatocellular Carcinoma and Contributes to the Proliferation and Migration of Hepatocellular Carcinoma Cells vol.36, pp.6, 2017, https://doi.org/10.1089/dna.2016.3626
  5. A miRNA-HERC4 pathway promotes breast tumorigenesis by inactivating tumor suppressor LATS1 pp.1674-8018, 2019, https://doi.org/10.1007/s13238-019-0607-2